These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 24216320)
1. Current status and future prospects of toxicogenomics in drug discovery. Khan SR; Baghdasarian A; Fahlman RP; Michail K; Siraki AG Drug Discov Today; 2014 May; 19(5):562-78. PubMed ID: 24216320 [TBL] [Abstract][Full Text] [Related]
2. Toxicogenomics in drug discovery: from preclinical studies to clinical trials. Yang Y; Blomme EA; Waring JF Chem Biol Interact; 2004 Nov; 150(1):71-85. PubMed ID: 15522262 [TBL] [Abstract][Full Text] [Related]
3. The Japanese toxicogenomics project: application of toxicogenomics. Uehara T; Ono A; Maruyama T; Kato I; Yamada H; Ohno Y; Urushidani T Mol Nutr Food Res; 2010 Feb; 54(2):218-27. PubMed ID: 20041446 [TBL] [Abstract][Full Text] [Related]
4. Strategic applications of toxicogenomics in early drug discovery. Ryan TP; Stevens JL; Thomas CE Curr Opin Pharmacol; 2008 Oct; 8(5):654-60. PubMed ID: 18760379 [TBL] [Abstract][Full Text] [Related]
5. [Current and future views from pharmaceutical industry perspectives on development of antidepressants]. Arano I; Imaeda T Nihon Shinkei Seishin Yakurigaku Zasshi; 2011 Aug; 31(4):181-6. PubMed ID: 21941853 [TBL] [Abstract][Full Text] [Related]
6. Toxicogenomics in drug discovery and development -- making an impact. Wills Q; Mitchell C Altern Lab Anim; 2009 Sep; 37 Suppl 1():33-7. PubMed ID: 19807202 [TBL] [Abstract][Full Text] [Related]
7. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors. Ichimaru K; Toyoshima S; Uyama Y Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436 [No Abstract] [Full Text] [Related]
10. Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments. McGivern JV; Ebert AD Adv Drug Deliv Rev; 2014 Apr; 69-70():170-8. PubMed ID: 24309014 [TBL] [Abstract][Full Text] [Related]
11. Looking forward in pharmaceutical process chemistry. Davies IW; Welch CJ Science; 2009 Aug; 325(5941):701-4. PubMed ID: 19661417 [TBL] [Abstract][Full Text] [Related]
12. SimuGen Ltd: reliable, early prediction of drug toxicity with toxicogenomics, human cell culture and computational models. Wills Q Pharmacogenomics; 2007 Aug; 8(8):1081-4. PubMed ID: 17716240 [TBL] [Abstract][Full Text] [Related]
13. The state-of-the-art in predictive toxicogenomics. Fielden MR; Kolaja KL Curr Opin Drug Discov Devel; 2006 Jan; 9(1):84-91. PubMed ID: 16445120 [TBL] [Abstract][Full Text] [Related]
14. Current and future use of genomics data in toxicology: opportunities and challenges for regulatory applications. Goetz AK; Singh BP; Battalora M; Breier JM; Bailey JP; Chukwudebe AC; Janus ER Regul Toxicol Pharmacol; 2011 Nov; 61(2):141-53. PubMed ID: 21840362 [TBL] [Abstract][Full Text] [Related]
15. Toxicogenomics in predictive toxicology in drug development. Suter L; Babiss LE; Wheeldon EB Chem Biol; 2004 Feb; 11(2):161-71. PubMed ID: 15123278 [TBL] [Abstract][Full Text] [Related]
16. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Lienhardt C; Vernon A; Raviglione MC Curr Opin Pulm Med; 2010 May; 16(3):186-93. PubMed ID: 20216421 [TBL] [Abstract][Full Text] [Related]
17. Toxicogenomics in drug discovery and drug development: potential applications and future challenges. Khor TO; Ibrahim S; Kong AN Pharm Res; 2006 Aug; 23(8):1659-64. PubMed ID: 16858654 [TBL] [Abstract][Full Text] [Related]
20. Future of toxicogenomics and safety signatures: balancing public access to data with proprietary drug discovery. Fostel JM Pharmacogenomics; 2007 May; 8(5):425-30. PubMed ID: 17465705 [No Abstract] [Full Text] [Related] [Next] [New Search]